Elisabeth Ejerblad

Comorbidities and mutations including single- and multihit TET2 mutations in relation to outcome in chronic myelomonocytic leukaemia: a population-based study

Kynning, Matilda Kjellander; Westerberg, Ebba; Forsell, Linda; Creignou, Maria et al.

Part of British Journal of Haematology, p. 514-523, 2026

• DOI for Comorbidities and mutations including single- and multihit TET2 mutations in relation to outcome in chronic myelomonocytic leukaemia: a population-based study
• Download full text (pdf) of Comorbidities and mutations including single- and multihit TET2 mutations in relation to outcome in chronic myelomonocytic leukaemia: a population-based study

Validation of Guidelines for Genetic Investigation of Myeloid Neoplasms with Germline Predisposition: Results from a Prospective Cohort Study

Tesi, Bianca; Robelius, Anna; Baskin, Berivan; Lazarevic, Vladimir et al.

Part of Clinical Cancer Research, p. 3062-3071, 2025

• DOI for Validation of Guidelines for Genetic Investigation of Myeloid Neoplasms with Germline Predisposition: Results from a Prospective Cohort Study
• Download full text (pdf) of Validation of Guidelines for Genetic Investigation of Myeloid Neoplasms with Germline Predisposition: Results from a Prospective Cohort Study

Influence of Cytogenetics on the Outcome of Patients With High-Risk Myelodysplastic Syndrome Including Deletion 5q Treated With Azacitidine With or Without Lenalidomide

Rasmussen, Bengt; Nilsson, Lars; Tobiasson, Magnus; Jaedersten, Martin et al.

Part of Genes, Chromosomes and Cancer, 2025

• DOI for Influence of Cytogenetics on the Outcome of Patients With High-Risk Myelodysplastic Syndrome Including Deletion 5q Treated With Azacitidine With or Without Lenalidomide
• Download full text (pdf) of Influence of Cytogenetics on the Outcome of Patients With High-Risk Myelodysplastic Syndrome Including Deletion 5q Treated With Azacitidine With or Without Lenalidomide

Early transfusion patterns improve the Molecular International Prognostic Scoring System (IPSS-M) prediction in myelodysplastic syndromes

Creignou, Maria; Bernard, Elsa; Gasparini, Alessandro; Tranberg, Anna et al.

Part of Journal of Internal Medicine, p. 53-67, 2024

• DOI for Early transfusion patterns improve the Molecular International Prognostic Scoring System (IPSS-M) prediction in myelodysplastic syndromes
• Download full text (pdf) of Early transfusion patterns improve the Molecular International Prognostic Scoring System (IPSS-M) prediction in myelodysplastic syndromes

Patient-Specific Measurable Residual Disease Markers Predict Outcome in Patients With Myelodysplastic Syndrome and Related Diseases After Hematopoietic Stem-Cell Transplantation

Tobiasson, Magnus; Pandzic, Tatjana; Illman, Johanna; Nilsson, Lars et al.

Part of Journal of Clinical Oncology, 2024

• DOI for Patient-Specific Measurable Residual Disease Markers Predict Outcome in Patients With Myelodysplastic Syndrome and Related Diseases After Hematopoietic Stem-Cell Transplantation

Comorbidities and mutations including single- and multihit TET2 mutations in relation to outcome in chronic myelomonocytic leukaemia: a population-based study

Kynning, Matilda Kjellander; Westerberg, Ebba; Forsell, Linda; Creignou, Maria et al.

Part of British Journal of Haematology, p. 514-523, 2026

• DOI for Comorbidities and mutations including single- and multihit TET2 mutations in relation to outcome in chronic myelomonocytic leukaemia: a population-based study
• Download full text (pdf) of Comorbidities and mutations including single- and multihit TET2 mutations in relation to outcome in chronic myelomonocytic leukaemia: a population-based study

Validation of Guidelines for Genetic Investigation of Myeloid Neoplasms with Germline Predisposition: Results from a Prospective Cohort Study

Tesi, Bianca; Robelius, Anna; Baskin, Berivan; Lazarevic, Vladimir et al.

Part of Clinical Cancer Research, p. 3062-3071, 2025

• DOI for Validation of Guidelines for Genetic Investigation of Myeloid Neoplasms with Germline Predisposition: Results from a Prospective Cohort Study
• Download full text (pdf) of Validation of Guidelines for Genetic Investigation of Myeloid Neoplasms with Germline Predisposition: Results from a Prospective Cohort Study

Influence of Cytogenetics on the Outcome of Patients With High-Risk Myelodysplastic Syndrome Including Deletion 5q Treated With Azacitidine With or Without Lenalidomide

Rasmussen, Bengt; Nilsson, Lars; Tobiasson, Magnus; Jaedersten, Martin et al.

Part of Genes, Chromosomes and Cancer, 2025

• DOI for Influence of Cytogenetics on the Outcome of Patients With High-Risk Myelodysplastic Syndrome Including Deletion 5q Treated With Azacitidine With or Without Lenalidomide
• Download full text (pdf) of Influence of Cytogenetics on the Outcome of Patients With High-Risk Myelodysplastic Syndrome Including Deletion 5q Treated With Azacitidine With or Without Lenalidomide

Early transfusion patterns improve the Molecular International Prognostic Scoring System (IPSS-M) prediction in myelodysplastic syndromes

Creignou, Maria; Bernard, Elsa; Gasparini, Alessandro; Tranberg, Anna et al.

Part of Journal of Internal Medicine, p. 53-67, 2024

• DOI for Early transfusion patterns improve the Molecular International Prognostic Scoring System (IPSS-M) prediction in myelodysplastic syndromes
• Download full text (pdf) of Early transfusion patterns improve the Molecular International Prognostic Scoring System (IPSS-M) prediction in myelodysplastic syndromes

Patient-Specific Measurable Residual Disease Markers Predict Outcome in Patients With Myelodysplastic Syndrome and Related Diseases After Hematopoietic Stem-Cell Transplantation

Tobiasson, Magnus; Pandzic, Tatjana; Illman, Johanna; Nilsson, Lars et al.

Part of Journal of Clinical Oncology, 2024

• DOI for Patient-Specific Measurable Residual Disease Markers Predict Outcome in Patients With Myelodysplastic Syndrome and Related Diseases After Hematopoietic Stem-Cell Transplantation

Therapy-related MDS dissected based on primary disease and treatment: a nationwide perspective

Moreno Berggren, Daniel; Garelius, Hege; Willner Hjelm, Petter; Nilsson, Lars et al.

Part of Leukemia, p. 1103-1112, 2023

• DOI for Therapy-related MDS dissected based on primary disease and treatment: a nationwide perspective
• Download full text (pdf) of Therapy-related MDS dissected based on primary disease and treatment: a nationwide perspective

MDS-Comorbidity Index using register data has prognostic impact in Swedish MDS patients

Larfors, Gunnar; Moreno Berggren, Daniel; Garelius, Hege; Nilsson, Lars et al.

Part of Leukemia Research, 2023

• DOI for MDS-Comorbidity Index using register data has prognostic impact in Swedish MDS patients
• Download full text (pdf) of MDS-Comorbidity Index using register data has prognostic impact in Swedish MDS patients

"Randomized phase II study of azacitidine +/- lenalidomide in higher-risk myelodysplastic syndromes and acute myeloid leukemia with a karyotype including Del(5q)"

Rasmussen, Bengt; Gohring, Gudrun; Bernard, Elsa; Nilsson, Lars et al.

Part of Leukemia, p. 1436-1439, 2022

• DOI for "Randomized phase II study of azacitidine +/- lenalidomide in higher-risk myelodysplastic syndromes and acute myeloid leukemia with a karyotype including Del(5q)"
• Download full text (pdf) of "Randomized phase II study of azacitidine +/- lenalidomide in higher-risk myelodysplastic syndromes and acute myeloid leukemia with a karyotype including Del(5q)"

Failure to reach hematopoietic allogenic stem cell transplantation in patients with myelodysplastic syndromes planned for transplantation: a population-based study

Lindholm, C.; Olofsson, E.; Creignou, M.; Nilsson, L. et al.

Part of Bone Marrow Transplantation, p. 598-606, 2022

• DOI for Failure to reach hematopoietic allogenic stem cell transplantation in patients with myelodysplastic syndromes planned for transplantation: a population-based study
• Download full text (pdf) of Failure to reach hematopoietic allogenic stem cell transplantation in patients with myelodysplastic syndromes planned for transplantation: a population-based study

Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Myelomonocytic Leukemia: Clinical and Molecular Genetic Prognostic Factors in a Nordic Population

Wedge, Eileen; Hansen, Jakob Werner; Dybedal, Ingunn; Creignou, Maria et al.

Part of Transplantation and Cellular Therapy, p. 9910-991000000000, 2021

• DOI for Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Myelomonocytic Leukemia: Clinical and Molecular Genetic Prognostic Factors in a Nordic Population

Prognostic scoring systems and comorbidities in chronic myelomonocytic leukaemia: a nationwide population-based study

Moreno Berggren, Daniel; Kjellander, Matilda; Backlund, Ellen; Engvall, Marie et al.

Part of British Journal of Haematology, p. 474-483, 2021

• DOI for Prognostic scoring systems and comorbidities in chronic myelomonocytic leukaemia: a nationwide population-based study
• Download full text (pdf) of Prognostic scoring systems and comorbidities in chronic myelomonocytic leukaemia: a nationwide population-based study

Income, education and their impact on treatments and survival in patients with myelodysplastic syndromes

Larfors, Gunnar; Moreno Berggren, Daniel; Garelius, Hege; Jadersten, Martin et al.

Part of European Journal of Haematology, p. 219-228, 2021

• DOI for Income, education and their impact on treatments and survival in patients with myelodysplastic syndromes
• Download full text (pdf) of Income, education and their impact on treatments and survival in patients with myelodysplastic syndromes

Inflammatory functional iron deficiency common in myelofibrosis, contributes to anaemia and impairs quality of life. From the Nordic MPN study Group

Birgegård, Gunnar; Samuelsson, Jan; Ahlstrand, Erik; Ejerblad, Elisabeth et al.

Part of European Journal of Haematology, p. 235-240, 2019

• DOI for Inflammatory functional iron deficiency common in myelofibrosis, contributes to anaemia and impairs quality of life. From the Nordic MPN study Group

Prognostic scoring systems for myelodysplastic syndromes (MDS) in a population-based setting: a report from the Swedish MDS register

Berggren, Daniel Moreno; Folkvaljon, Yasin; Engvall, Marie; Sundberg, Johan et al.

Part of British Journal of Haematology, p. 614-627, 2018

• DOI for Prognostic scoring systems for myelodysplastic syndromes (MDS) in a population-based setting: a report from the Swedish MDS register

Targeted Sequencing of A Cohort Of 385 Patients With Myelodysplastic Syndromes: A Multicenter, Population-Based Study From Sweden

Creignou, M.; Ejerblad, Elisabeth; Antunovic, P.; Garelius, H. et al.

Part of Leukemia Research, 2017

METHYLATION AGE IN MPN PATIENTS AS A CORRELATE FOR DISEASE STATUS, ALLELE BURDEN AND THERAPEUTIC RESPONSE

McPherson, S.; McCourt, P.; Ejerblad, Elisabeth; Zweegman, S. et al.

Part of Haematologica, p. 278-279, 2017

Validation Of Prognostic Scoring Systems For Myelodysplastic Syndromes In The Swedish Mds-Register

Berggren, Daniel Moreno; Folkvaljon, Y.; Engvall, M.; Sundberg, J. et al.

Part of Haematologica, p. 243-243, 2016

Recent results of allogeneic stem cell transplantation for myelofibrosis using reduced intensity conditioning - the Swedish experience

Lenhoff, S.; Dreimane, A.; Ejerblad, Elisabeth; Isaksson, C. et al.

Part of Bone Marrow Transplantation, 2015

Circulating YKL-40 in patients with essential thrombocythemia and polycythemia vera treated with the novel histone deacetylase inhibitor vorinostat

Andersen, Christen Lykkegaard; Bjorn, Mads Emil; McMullin, Mary Frances; Harrison, Claire et al.

Part of Leukemia Research, p. 816-821, 2014

• DOI for Circulating YKL-40 in patients with essential thrombocythemia and polycythemia vera treated with the novel histone deacetylase inhibitor vorinostat

Influence of IL-28B and IL-6 Genetic Polymorphism on IFN-ALFA Treatment Outcome in Patients with Polycythemia Vera and Essential Trombocythemia

Lindgren, M.; Samuelsson, J.; Nilsson, L.; Knutsen, H. et al.

Part of Haematologica, p. 130-131, 2014

A Retrospective Cohort Study of Interferon-alpha Therapy in Myeloproliferative Neoplasms; Adverse Events, Thromboembolic Incidence and Causes of Termination of Therapy

Lindgren, Marie; Samuelsson, Jan; Nilsson, Lars; Knutsen, Havar et al.

Part of Blood, 2014

Diagnosis according to World Health Organization determines the long-term prognosis in patients with myeloproliferative neoplasms treated with anagrelide: Results of a prospective long-term follow-up

Ejerblad, Elisabeth; Kvasnicka, Hans M; Thiele, Jürgen; Andreasson, Björn et al.

Part of Hematology, p. 8-13, 2013

• DOI for Diagnosis according to World Health Organization determines the long-term prognosis in patients with myeloproliferative neoplasms treated with anagrelide: Results of a prospective long-term follow-up

Patients with polycythemia vera have worst impairment of quality of life among patients with newly diagnosed myeloproliferative neoplasms

Abelsson, Johanna; Andreasson, Bjorn; Samuelsson, Jan; Hultcrantz, Malin et al.

Part of Leukemia and Lymphoma, p. 2226-2230, 2013

• DOI for Patients with polycythemia vera have worst impairment of quality of life among patients with newly diagnosed myeloproliferative neoplasms

A phase II study of vorinostat (MK-0683) in patients with polycythaemia vera and essential thrombocythaemia

Andersen, Christen L.; McMullin, Mary F.; Ejerblad, Elisabeth; Zweegman, Sonja et al.

Part of British Journal of Haematology, p. 498-508, 2013

• DOI for A phase II study of vorinostat (MK-0683) in patients with polycythaemia vera and essential thrombocythaemia

Obesity and Risk for Chronic Renal Failure.

Ejerblad, Elisabeth; Fored, CM; Lindblad, P; Fryzek, J et al.

Part of J Am Soc Nephrol, 2006